BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27091416)

  • 1. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
    Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
    Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
    J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine: a review of its use in older patients with acute myeloid leukaemia.
    Curran MP
    Drugs Aging; 2013 Jun; 30(6):447-58. PubMed ID: 23580320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Thomas XG; Arthur C; Delaunay J; Jones M; Berrak E; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):68-72. PubMed ID: 24220616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).
    Tomeczkowski J; Lange A; Güntert A; Thilakarathne P; Diels J; Xiu L; De Porre P; Tapprich C
    Adv Ther; 2015 Sep; 32(9):854-62. PubMed ID: 26369324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
    Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
    Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine. Acute myeloid leukaemia: no progress.
    Prescrire Int; 2014 Apr; 23(148):92-4. PubMed ID: 24860891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
    Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F
    Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
    Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
    Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
    Mayer J; Arthur C; Delaunay J; Mazur G; Thomas XG; Wierzbowska A; Ravandi F; Berrak E; Jones M; Li Y; Kantarjian HM
    BMC Cancer; 2014 Feb; 14():69. PubMed ID: 24498872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.